Assunta Sgambato

956 total citations
31 papers, 742 citations indexed

About

Assunta Sgambato is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Assunta Sgambato has authored 31 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Assunta Sgambato's work include Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (14 papers) and Cancer therapeutics and mechanisms (8 papers). Assunta Sgambato is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (14 papers) and Cancer therapeutics and mechanisms (8 papers). Assunta Sgambato collaborates with scholars based in Italy, Spain and United States. Assunta Sgambato's co-authors include Cesare Gridelli, Francesca Casaluce, Paolo Maione, Fortunato Ciardiello, Antônio Rossi, Paola Claudia Sacco, Giovanni Palazzolo, Alex A. Adjei, Solange Peters and Giuseppe Santabarbara and has published in prestigious journals such as Current Medicinal Chemistry, Current Pharmaceutical Design and Cancer Treatment Reviews.

In The Last Decade

Assunta Sgambato

31 papers receiving 729 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Assunta Sgambato Italy 15 441 416 293 125 66 31 742
Francesca Casaluce Italy 15 512 1.2× 462 1.1× 326 1.1× 140 1.1× 82 1.2× 38 841
Paola Claudia Sacco Italy 18 505 1.1× 438 1.1× 340 1.2× 135 1.1× 89 1.3× 42 889
Joseph Chen United States 13 452 1.0× 527 1.3× 240 0.8× 110 0.9× 37 0.6× 27 801
Jih‐Hsiang Lee Taiwan 19 669 1.5× 561 1.3× 347 1.2× 196 1.6× 73 1.1× 37 1.0k
Sara Baglivo Italy 17 661 1.5× 541 1.3× 306 1.0× 187 1.5× 109 1.7× 39 993
Caicun Zhou China 12 435 1.0× 393 0.9× 197 0.7× 106 0.8× 82 1.2× 36 710
Silvia Paola Corona Italy 13 391 0.9× 357 0.9× 230 0.8× 152 1.2× 32 0.5× 43 689
Ken Uchibori Japan 15 567 1.3× 614 1.5× 360 1.2× 156 1.2× 67 1.0× 59 885
Tahsin M. Khan United States 8 344 0.8× 364 0.9× 275 0.9× 115 0.9× 26 0.4× 23 604
Maria Anna Bareschino Italy 16 382 0.9× 381 0.9× 297 1.0× 95 0.8× 30 0.5× 27 707

Countries citing papers authored by Assunta Sgambato

Since Specialization
Citations

This map shows the geographic impact of Assunta Sgambato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Assunta Sgambato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Assunta Sgambato more than expected).

Fields of papers citing papers by Assunta Sgambato

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Assunta Sgambato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Assunta Sgambato. The network helps show where Assunta Sgambato may publish in the future.

Co-authorship network of co-authors of Assunta Sgambato

This figure shows the co-authorship network connecting the top 25 collaborators of Assunta Sgambato. A scholar is included among the top collaborators of Assunta Sgambato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Assunta Sgambato. Assunta Sgambato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Casaluce, Francesca, et al.. (2018). Lung cancer, elderly and immune checkpoint inhibitors. Journal of Thoracic Disease. 10(S13). S1474–S1481. 22 indexed citations
2.
Gridelli, Cesare, Paul Baas, Fabrice Barlési, et al.. (2017). Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer. 19(4). 301–314. 8 indexed citations
3.
Gridelli, Cesare, Paolo A. Ascierto, Massimo Barberis, et al.. (2016). Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Expert Opinion on Biological Therapy. 16(12). 1479–1489. 12 indexed citations
4.
Casaluce, Francesca, Assunta Sgambato, Giovanni Palazzolo, et al.. (2016). Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies. Current Clinical Pharmacology. 11(2). 77–87. 26 indexed citations
5.
Rossi, Antônio, Paola Claudia Sacco, Assunta Sgambato, et al.. (2016). Optimal drugs for second-line treatment of patients with small-cell lung cancer. Expert Opinion on Pharmacotherapy. 17(7). 969–976. 13 indexed citations
6.
7.
Sacco, Paola Claudia, Paolo Maione, Antônio Rossi, et al.. (2015). Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer. Expert Review of Respiratory Medicine. 9(3). 245–254. 3 indexed citations
8.
Maione, Paolo, Antônio Rossi, Assunta Sgambato, et al.. (2015). New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer. Current Pharmaceutical Design. 21(32). 4763–4772. 4 indexed citations
9.
Rossi, Emanuela, Assunta Sgambato, Francesca Casaluce, et al.. (2015). Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. Expert Review of Clinical Pharmacology. 9(3). 419–428. 23 indexed citations
10.
Sacco, Paola Claudia, Francesca Casaluce, Assunta Sgambato, et al.. (2015). Current challenges of lung cancer care in an aging population. Expert Review of Anticancer Therapy. 15(12). 1419–1429. 9 indexed citations
11.
Sgambato, Assunta, Francesca Casaluce, Paola Claudia Sacco, et al.. (2015). Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. Current Drug Safety. 11(1). 62–68. 63 indexed citations
12.
Maione, Paolo, Antônio Rossi, Clorinda Schettino, et al.. (2014). Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC. Current Pharmaceutical Design. 20(24). 3894–3900. 10 indexed citations
13.
Casaluce, Francesca, Assunta Sgambato, Paola Claudia Sacco, et al.. (2014). Emerging drugs targeting PD-1 and PD-L1: reality or hope?. Expert Opinion on Emerging Drugs. 19(4). 557–569. 10 indexed citations
14.
Rossi, Antônio, Paolo Maione, Paola Claudia Sacco, et al.. (2014). ALK inhibitors and advanced non-small cell lung cancer (Review). International Journal of Oncology. 45(2). 499–508. 26 indexed citations
15.
Sgambato, Assunta, Francesca Casaluce, Paolo Maione, et al.. (2013). Medical treatment of small cell lung cancer: state of the art and new development. Expert Opinion on Pharmacotherapy. 14(15). 2019–2031. 20 indexed citations
16.
Casaluce, Francesca, Assunta Sgambato, Paolo Maione, Fortunato Ciardiello, & Cesare Gridelli. (2013). Emerging mitotic inhibitors for non-small cell carcinoma. Expert Opinion on Emerging Drugs. 18(1). 97–107. 10 indexed citations
17.
Gridelli, Cesare, Solange Peters, Assunta Sgambato, et al.. (2013). ALK inhibitors in the treatment of advanced NSCLC. Cancer Treatment Reviews. 40(2). 300–306. 142 indexed citations
18.
Maione, Paolo, et al.. (2013). Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.. Reviews on Recent Clinical Trials. 8(2). 93–100. 12 indexed citations
19.
Schettino, Clorinda, Maria Anna Bareschino, Paolo Maione, et al.. (2013). New Molecular Targets in the Treatment of NSCLC. Current Pharmaceutical Design. 19(30). 5333–5343. 24 indexed citations
20.
Sgambato, Assunta, Francesca Casaluce, Paolo Maione, et al.. (2012). The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer. Current Pharmaceutical Design. 18(37). 6155–6168. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Casaluce Breakdown of academic impact, for papers by Paola Claudia Sacco Breakdown of academic impact, for papers by Joseph Chen Breakdown of academic impact, for papers by Jih‐Hsiang Lee Breakdown of academic impact, for papers by Sara Baglivo Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Silvia Paola Corona Breakdown of academic impact, for papers by Ken Uchibori Breakdown of academic impact, for papers by Tahsin M. Khan Breakdown of academic impact, for papers by Maria Anna Bareschino
Rankless by CCL
2026